Control study of melphalan instead of cyclophosphamide as a myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation for treatment of myeloid malignancies / 中华血液学杂志
Chinese Journal of Hematology
; (12): 835-839, 2015.
Article
en Zh
| WPRIM
| ID: wpr-296140
Biblioteca responsable:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate melphalan instead of cyclophosphamide in modified busulfancyclophosphamide regimen as a new myeloablative conditioning regimen for the treatment of myeloid malignancies patients receiving allogeneic hematopoietic stem cell transplantation (HSCT).</p><p><b>METHODS</b>The clinic data of 94 myeloid malignancies patients undergoing allogeneic HSCT were analyzed, of which 48 patients received Bu+Cy+Flu+Ara-C, 46 cases Bu+Mel+Flu+Ara-C regimens. Rregimen-related toxicity, engraftment, graft- versus-host disease(GVHD), infection condition, non- relapse mortality, and overall survival were compared between the two groups.</p><p><b>RESULTS</b>All patients achieved neutrophil engraftment. The incidence of grade Ⅲ-Ⅳ oral mucositis and diarrhea in BMFA group was higher than in BCFA group(P<0.05). The incidence of acute GVHD in BMFA group was also higher than in BCFA group but without statistically significant difference(36.5% over 56.5%, P=0.100). With a median follow up of 42 months, the incidence of no relapse mortality in BCFA group was 12.5% and 19.6% in BMFA group(P=0.400). The relapse rate in BMFA group(4.3%)was significantly lower than in BCFA group (25.0%, P=0.009). The overall survival rates were(71.8±6.7)% and(76.1±6.3)%(P=0.852), and diseasefree survival rates were(67.8±8.9)% and(76.1±6.3)%(P=0.567)were comparable between BCFA group and BMFA group.</p><p><b>CONCLUSION</b>Melphalan instead of cyclophosphamide as a new myeloablative conditioning regimen had lower relapse and satisfied disease-free survival rates, but the risk of regimenrelated toxicity and GVHD should be taken into consideration.</p>
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Terapéutica
/
Trasplante Homólogo
/
Inducción de Remisión
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Tasa de Supervivencia
/
Trasplante de Células Madre Hematopoyéticas
/
Supervivencia sin Enfermedad
/
Neoplasias Hematológicas
/
Acondicionamiento Pretrasplante
/
Ciclofosfamida
Límite:
Humans
Idioma:
Zh
Revista:
Chinese Journal of Hematology
Año:
2015
Tipo del documento:
Article